Lung cancer screening and the national lung screening trial (NLST)

Fabien Maldonado, Eric Edell

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [Jemal A et al., CA Cancer J Clin 61:69-9, 2011; Siegel R et al., CA Cancer J Clin 61:212-6, 2011]. In spite of major advances achieved in lung cancer diagnosis, medical, surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16 % [Goldstraw P et al., J Thorac Oncol 2:706-14, 2007]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65 %, 88 % and 99 %, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.

Original languageEnglish (US)
Title of host publicationInterventions in Pulmonary Medicine
PublisherSpringer New York
Pages251-259
Number of pages9
ISBN (Electronic)9781461460091
ISBN (Print)1461460085, 9781461460084
DOIs
StatePublished - Oct 1 2013

Fingerprint

Early Detection of Cancer
Lung Neoplasms
Lung
Neoplasms
Colonic Neoplasms
Palliative Care
Prostate
Prostatic Neoplasms
Breast
Survival Rate
Breast Neoplasms
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Maldonado, F., & Edell, E. (2013). Lung cancer screening and the national lung screening trial (NLST). In Interventions in Pulmonary Medicine (pp. 251-259). Springer New York. https://doi.org/10.1007/978-1-4614-6009-1_17

Lung cancer screening and the national lung screening trial (NLST). / Maldonado, Fabien; Edell, Eric.

Interventions in Pulmonary Medicine. Springer New York, 2013. p. 251-259.

Research output: Chapter in Book/Report/Conference proceedingChapter

Maldonado, F & Edell, E 2013, Lung cancer screening and the national lung screening trial (NLST). in Interventions in Pulmonary Medicine. Springer New York, pp. 251-259. https://doi.org/10.1007/978-1-4614-6009-1_17
Maldonado F, Edell E. Lung cancer screening and the national lung screening trial (NLST). In Interventions in Pulmonary Medicine. Springer New York. 2013. p. 251-259 https://doi.org/10.1007/978-1-4614-6009-1_17
Maldonado, Fabien ; Edell, Eric. / Lung cancer screening and the national lung screening trial (NLST). Interventions in Pulmonary Medicine. Springer New York, 2013. pp. 251-259
@inbook{2a5de478efc84a88b9f2a4066e7ebf13,
title = "Lung cancer screening and the national lung screening trial (NLST)",
abstract = "Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [Jemal A et al., CA Cancer J Clin 61:69-9, 2011; Siegel R et al., CA Cancer J Clin 61:212-6, 2011]. In spite of major advances achieved in lung cancer diagnosis, medical, surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16 {\%} [Goldstraw P et al., J Thorac Oncol 2:706-14, 2007]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65 {\%}, 88 {\%} and 99 {\%}, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.",
author = "Fabien Maldonado and Eric Edell",
year = "2013",
month = "10",
day = "1",
doi = "10.1007/978-1-4614-6009-1_17",
language = "English (US)",
isbn = "1461460085",
pages = "251--259",
booktitle = "Interventions in Pulmonary Medicine",
publisher = "Springer New York",

}

TY - CHAP

T1 - Lung cancer screening and the national lung screening trial (NLST)

AU - Maldonado, Fabien

AU - Edell, Eric

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [Jemal A et al., CA Cancer J Clin 61:69-9, 2011; Siegel R et al., CA Cancer J Clin 61:212-6, 2011]. In spite of major advances achieved in lung cancer diagnosis, medical, surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16 % [Goldstraw P et al., J Thorac Oncol 2:706-14, 2007]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65 %, 88 % and 99 %, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.

AB - Lung cancer remains the most common cause of cancer-related deaths in the USA and worldwide. An estimated 220,000 new cases are diagnosed, while nearly 160,000 patients die from lung cancer each year in the USA alone, accounting for more cancer-related deaths than the next three most common cancers combined: colon, breast, and prostate [Jemal A et al., CA Cancer J Clin 61:69-9, 2011; Siegel R et al., CA Cancer J Clin 61:212-6, 2011]. In spite of major advances achieved in lung cancer diagnosis, medical, surgical treatment, and palliative care, the overall 5-year survival for lung cancer has not noticeably changed over the past 20 years and is estimated around 16 % [Goldstraw P et al., J Thorac Oncol 2:706-14, 2007]. These dismal statistics compare poorly with those of other common cancers such as colon, breast, and prostate cancers characterized by 5-year survival rates of 65 %, 88 % and 99 %, respectively. Among the many potential explanations advanced to explain such differences, the lack of effective screening for lung cancer is often contrasted to what are generally assumed and accepted screening strategies for those other malignancies. Lung cancer is in the majority of cases diagnosed at advanced stages, as symptoms prompt patients to seek medical attention, when curative therapeutic options are at best limited.

UR - http://www.scopus.com/inward/record.url?scp=84929534851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929534851&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-6009-1_17

DO - 10.1007/978-1-4614-6009-1_17

M3 - Chapter

AN - SCOPUS:84929534851

SN - 1461460085

SN - 9781461460084

SP - 251

EP - 259

BT - Interventions in Pulmonary Medicine

PB - Springer New York

ER -